An announcement from Actuate Therapeutics, Inc. ( (ACTU) ) is now available.
On May 6, 2025, Actuate Therapeutics announced positive topline results from its Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). The trial showed statistically significant improvements in overall survival and a favorable risk-benefit profile, meeting its primary endpoint. These results, which will be presented at the ASCO Annual Meeting, suggest a potential shift in the treatment paradigm for mPDAC, and the company plans to work with regulators to expedite elraglusib’s commercialization.
More about Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers. The company’s lead investigational drug, elraglusib, is a novel GSK-3β inhibitor targeting cancer molecular pathways that promote tumor growth and resistance to conventional cancer treatments.
Average Trading Volume: 41,811
Technical Sentiment Signal: Strong Buy
For an in-depth examination of ACTU stock, go to TipRanks’ Stock Analysis page.